Focused on treatments for rare neurological diseases, the company is a clinical‑stage biotechnology developer advancing therapies that use autologous red blood cells to deliver drugs. Its lead program, EryDex, is being studied as a potential treatment for ataxia‑telangiectasia, a rare inherited diso...
1 member of Congress has disclosed 1 trade in Quince Therapeutics Inc (QNCX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-05-12 | Rohit Khanna | buy | $1K – $15K |